Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules in strengths of 1 mg, 2 mg, 3 mg and 4 mg in the United States market. The launch marks a significant expansion of the company’s oncology portfolio in the highly competitive US generics market.
The newly launched product is the generic equivalent of Pomalyst® Capsules, a drug marketed by Bristol Myers Squibb. Eugia Pharma was among the First-to-File (FTF) ANDA applicants for the product, providing the company with a strategic entry into a large-value therapeutic segment.
According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately $3.3 billion in the United States, highlighting the strong commercial potential for the generic version.
Pomalidomide is a third-generation immunomodulatory drug (IMiD) primarily used in the treatment of relapsed or refractory multiple myeloma, typically administered in combination with dexamethasone and sometimes bortezomib. The drug is also indicated for the treatment of AIDS-related Kaposi sarcoma, making it an important therapy in oncology and immunology.
The capsules will be manufactured at Eugia Unit-I, one of the company’s facilities dedicated to oncology and specialty pharmaceutical products.
Hyderabad-headquartered Aurobindo Pharma is a global pharmaceutical company engaged in the development, manufacturing and commercialization of generic medicines, specialty pharmaceuticals and active pharmaceutical ingredients (APIs). The company sells its products in more than 150 countries worldwide.
Aurobindo Pharma currently operates over 30 manufacturing and packaging facilities approved by major global regulatory authorities including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC and Brazil ANVISA.